La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

LianBio Gestione

Gestione criteri di controllo 1/4

LianBio's Il CEO è Adam Stone, nominato in Dec2023, ha un mandato di meno di un anno. possiede direttamente 0.016% delle azioni della società, per un valore di $ 5.54K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.7 anni e 2.8 anni.

Informazioni chiave

Adam Stone

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.02%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	2.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Adam Stone (44 yo)

less than a year

Mandato

US$62,073

Compensazione

Mr. Adam Leo Stone is Chief Investment Officer & Head of Research of Perceptive Advisors LLC. He joined the Perceptive Advisors LLC in 2006. He serves as CEO & Director at Perceptive Capital Solutions Corp...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Konstantin Poukalov	Founder & Executive Chairman	4.9yrs	US$62.07k	0.016% $ 5.0k
Adam Stone	Interim CEO & Director	less than a year	US$62.07k	0.016% $ 5.0k
Ehong Gu	Interim CFO	less than a year	Nessun dato	0% $ 0
Ji Chen	Senior VP & General Counsel	no data	Nessun dato	Nessun dato
Brianne Jahn	Chief Business Officer	3yrs	US$2.69m	Nessun dato
Levvy Lv Eng	Senior VP & Global Head of Development	no data	Nessun dato	Nessun dato

0.8yrs

Durata media

40yo

Età media

Gestione esperta: Il team dirigenziale di LIAN.Y non è considerato esperto (durata media 0.7 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Konstantin Poukalov	Founder & Executive Chairman	4.9yrs	US$62.07k	0.016% $ 5.0k
Adam Stone	Interim CEO & Director	4.9yrs	US$62.07k	0.016% $ 5.0k
Tassos Anastasios Gianakakos	Independent Director	4.1yrs	US$128.07k	0.34% $ 107.3k
Susan Silbermann	Independent Director	2.9yrs	US$121.44k	0.016% $ 5.0k
Neil Kumar	Director	4.9yrs	Nessun dato	0% $ 0
Elliott Levy	Member of Scientific Advisory Board	2.4yrs	Nessun dato	Nessun dato
Mathias Hukkelhoven	Member of Scientific Advisory Board	2.4yrs	Nessun dato	Nessun dato
Wei Chen	Independent Director	2.4yrs	US$285.89k	0% $ 0
Zhao Yan	Member of Scientific Advisory Board	2.4yrs	Nessun dato	Nessun dato

2.9yrs

Durata media

54.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di LIAN.Y non è considerato esperto (durata media del mandato 2.8 anni), il che suggerisce un nuovo consiglio.

LianBio Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

LianBio Announces Chief Financial Officer Changes

LianBio Announces Chief Financial Officer Changes

Lianbio Announces Chief Executive Officer Changes

LianBio Announces the Resignation of Debra Yu, M.D. as President and Chief Strategy Officer, Effective January 1, 2023

Less than half of directors are independent

Less than half of directors are independent

Recent updates

LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index

With No Cure In Sight, Drugs Firm LianBio Begins Exit Strategy

LianBio Intends to File Form 25 with SEC

LianBio Announces Chief Financial Officer Changes

LianBio Announces Chief Financial Officer Changes

Lianbio Announces Chief Executive Officer Changes

Concentra Biosciences, LLC cancelled the acquisition of LianBio (NasdaqGM:LIAN) from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.

LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

New major risk - Revenue and earnings growth

LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023

Price target decreased by 19% to US$6.24

Forecast to breakeven in 2023

LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

LianBio (NASDAQ:LIAN) Is In A Good Position To Deliver On Growth Plans

Lianbio Announces Marketing Approval of CAMZYOS®? (Mavacamten) in Singapore

LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in the Macau Special Administrative Region (SAR) of China

We're Hopeful That LianBio (NASDAQ:LIAN) Will Use Its Cash Wisely

Price target decreased to US$8.23

We Think LianBio (NASDAQ:LIAN) Can Afford To Drive Business Growth

LianBio Announces the Resignation of Debra Yu, M.D. as President and Chief Strategy Officer, Effective January 1, 2023

Less than half of directors are independent

Price target increased to US$12.00

LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors

LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

Companies Like LianBio (NASDAQ:LIAN) Are In A Position To Invest In Growth

Lianbio Completes Enrollment in Pivotal Phase 3 EXPLORER-CNTrial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients

Will LianBio (NASDAQ:LIAN) Spend Its Cash Wisely?

LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers

U.S. Food and Drug Administration Approves Camzyos (Mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Less than half of directors are independent

LianBio Announces Formation of Scientific Advisory Board

LianBio Appoints Wei Wei Chen to Board of Directors

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

Here's Why LianBio (NASDAQ:LIAN) Must Use Its Cash Wisely

Lianbio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy

LianBio Announces Approval of Infigratinib Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China

No independent directors

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media